Sermorelin research: studies, doses and safety

An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.

Also called: Sermorelin acetate, Geref, GHRH(1-29)-NH2, GRF(1-29)-NH2, Groliberin.

GHRH analogues · Growth hormone-releasing hormone receptor agonist.

A growth-hormone-deficiency study in children used nightly injections for up to 12 months; this does not define an adult wellness course.

35 human reports include two spontaneous safety reports, excluding a duplicate substudy and two registry records. The full count and participant overlap remain uncertain.

Key studies

  • Geref: daily pediatric treatment: Growth speed rose in some children with GH deficiency; this does not establish adult wellness benefits. (source)
  • Children: 30 or 60 mcg/kg/day: Doubling the GHRH infusion dose did not improve growth. (source)
  • Children: three daily injections: Split-dose GHRH promoted growth, but the findings apply to GH-deficient children. (source)
  • IV and nasal dose finding: Nasal delivery required far higher doses and had low absorption. (source)
  • Nasal treatment lost effect: This nasal formulation did not sustain growth benefits. (source)
  • Six-month infusion: fading GH response: The hormone response weakened during prolonged infusion. (source)

Related to Sermorelin

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.